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a b s t r a c t
Type-2/eosinophilic inﬂammation plays a pivotal role in asthma. The identiﬁcation of severe type-2/
eosinophilic asthma is important for improving the management of patients with asthma. Therefore,
efforts to develop non-invasive biomarkers for type-2/eosinophilic airway inﬂammation have been made
during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are
considered markers of type-2/eosinophilic inﬂammation in asthma. However, a single-marker approach
has limited the ability to diagnose severe type-2/eosinophilic asthma accurately and predict disease
outcomes precisely. The present article reviews the utility of FeNO and serum periostin levels in a single-
marker approach and in a multiple-marker approach in identifying patients with severe type-2/
eosinophilic asthma. Furthermore, based on a sub-analysis of the Kinki Hokuriku Airway disease Con-
ference (KiHAC), geno-endo-phenotypes of patients were stratiﬁed into four groups according to the
FeNO and serum periostin levels.
Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Asthma has recently been recognized as an umbrella term that
encompasses various phenotypes and endotypes rather than a
single disease.1,2 Despite the diversity of endotypes and inﬂam-
matory patterns,3 type-2/eosinophilic inﬂammation remains a key
driver in nearly half of all patients with asthma4 and has been
demonstrated in airway epithelial cells isolated from patients with
mild-to-moderate asthma.5 Therefore, efforts to develop non-
invasive biomarkers for type-2/eosinophilic airway inﬂammation
have been made during this decade. Currently, fraction of exhaled
nitric oxide (FeNO) and serum periostin levels are considered bio-
markers of type-2/eosinophilic inﬂammation. In the present review
article, the strength and weakness of FeNO and serum periostin
levels as markers of type-2 inﬂammation are brieﬂy summarized,
which may facilitate improved interpretation of markers in the
management of asthma. Studies that compared the utility of two
markers to identify severe type-2/eosinophilic airway inﬂamma-
tion or to diagnose pediatric asthma are also reviewed. A single-
marker approach may be insufﬁcient to cover the whole range of
asthma management, from disease diagnosis to prediction of dis-
ease prognosis and response to treatments, even when limited to
the prediction of eosinophilic airway inﬂammation.6 However,
evidence regarding the use of a multiple-marker approach to
identify severe type-2/eosinophilic asthma is scarce.7,8 Herein, the
potential utility of a composite marker of FeNO and serum periostin
levels is presented based on a sub-analysis of the Kinki Hokuriku
Airway disease Conference (KiHAC). Geno-endo-phenotypes with
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either high FeNO levels only or serum perisotin levels only are also
described.
FeNO
Currently, FeNO is commonly used in the clinical settings of
asthma, and the measurement of FeNO at 50mL/s of expiratory ﬂow
using NIOX VERO® and NObreath® is generally accepted by health
insurance systems, including in Japan.9 The utility of this marker in
themanagement of asthma has beenwell-established and reviewed
elsewhere.10e12 In brief, NO is predominantly produced by inducible
NO synthase (iNOS), which is upregulated in airway epithelial cells,
macrophages, andother inﬂammatory cells in response to the type-2
inﬂammatory milieu in asthma. Elevated FeNO levels reﬂect
airway eosinophilic inﬂammation and aid the diagnosis of type-2/
eosinophilic asthma in symptomatic patients with cough, wheezes,
and dyspnea.11e13 Elevated FeNO levels predict good responses to
inhaled corticosteroid (ICS) treatment, particularly in ICS-naïve
patients with asthma.14,15 Basically, iNOS and FeNO levels are
steroid-sensitive, and elevated FeNO levels in patients treated with
ICS may indicate poor adherence to ICS.12,14,16,17 On the other hand,
elevated iNOS and FeNO may indicate ICS insensitivity or severe
type-2/eosinophilic asthma,12,18 which reﬂects a phenotype at an
increased risk of future exacerbations.19,20 Elevated FeNO levels also
reﬂect oxidative/nitrative stress in the airways, which drives ﬁbrosis
progression21 and may represent a marker of excess decline in pul-
monary function when sufﬁciently elevated.22,23 Thus, FeNO alone
may identify severe type-2 predominant asthma in real-world
settings. However, there may be a patient group, as discussed later,
with high FeNO levels that are asymptomatic and stable for pro-
longed periods without demonstrating excess decline in pulmonary
function. Themechanisms underlying the non-speciﬁc raise in FeNO
levels remain unknown but may be augmented by several factors
other than eosinophilic airway inﬂammation, such as height and
male gender (Table 1). Constitutive NOS, ofwhich sources are steroid
insensitive, may also be involved.24
Serum periostin
Serum periostin is considered another promising biomarker of
type-2/eosinophilic inﬂammation. Periostin expression is increased
by stimulation with interleukin (IL)-4, IL-13, and transforming
growth factor bmainly in airway ﬁbroblasts and epithelial cells.25e27
The utility of serum periostin in asthma management is also
reviewed elsewhere.27e31 Periostin, a matricellular protein, is a
downstream product of the type-2 pathway; promotes eosinophil
adhesion and recruitment to the airways32; and activates functions
of eosinophils, including O2 generation.33 Thus, high serum peri-
ostin levels are considered a marker of type-2/eosinophilic asthma
and airway remodeling that results in an accelerated decline in
pulmonary function.34 Similar to FeNO,35 high serum periostin
levels are often accompanied by eosinophilic chronic rhinosinusitis-
like conditions29,36 andmay predict treatment failurewhile tapering
ICS doses37 and good responses to biologics against type-2 pathway
in patients with asthma.38,39 In contrast with FeNO, serum periostin
levels are stable with a small coefﬁcient of variation40,41 and may
have a feature of ICS insensitivity.29,42 These similar but different
characteristics/modiﬁers indicate that high serum periostin levels
may imply a more static disease process, while FeNO levels reﬂect
more dynamic disease activity in patients with type-2/eosinophilic
asthma on ICS treatment.29 Although the precise mechanisms are
unknown, elevated serum periostin levels are less frequently
observed in obese patients with asthma,43 which is also reported in
a recent epidemiological study on serum periostin levels.44 Possibly
reﬂecting its ﬁbrosis-prone nature,45 serum periostin levels are
elevated in ﬁbrotic diseases, such as idiopathic interstitial pneu-
monia46 and scleroderma47 (Table 1).
Comparisons between FeNO and serum periostin in the
prediction of airway eosinophilia and diagnosis of pediatric
asthma
Efforts to identify the best single marker with sufﬁcient sensi-
tivity and speciﬁcity to predict airway eosinophilia is clinically
important. Although direct comparisons between FeNO levels and
serum periostin levels are rarely reported (Table 2), serum periostin
levels have been found to be the best predictor of airway eosino-
philia among FeNO, blood eosinophil counts, serum IgE, and serum
periostin in adult patients with severe asthma who remained
symptomatic despite receiving high doses of ICS treatment
(BOBCAT study) (n ¼ 67; 32 males; mean age, 46 years; FEV1, 60%;
daily ICS doses >1000 mg ﬂuticasone propionate equivalent;
Asthma Control Questionnaire score, 2.7).41 These results were not
observed in another study of patients with mild-to-moderate
asthma (n ¼ 110; 54 males; mean age, 49 years; FEV1, 100%; daily
ICS doses, 500 mg ﬂuticasone propionate equivalent).48 However,
the potential mechanisms underlying this discrepancy may be
attributable to differences in periostin assay systems and disease
severity among studied patients.49 A recent study of Japanese pe-
diatric patients with asthma reported a similar predictability of
serum periostin and FeNO in distinguishing children with asthma
from controls.50 Thus, results from a single-marker approach may
often depend on patient characteristics and the periostin assay kits
used. Thus, a multiple-marker approach is expected to improve the
accuracy in predicting severe type-2/eosinophilic asthma.
Combination of FeNO and serum periostin in the
management of severe asthma
In several diseases, such as pancreatic adenocarcinoma,51 Alz-
heimer's disease,52 and severe graft-versus-host disease,53 the su-
periority of a multiple-marker approach in terms of diagnostic
accuracy over a single-marker approach has been reported. In mild-
to-severe asthma, combinations of FeNO levels, blood eosinophil
counts, and serum total IgE levels demonstrated no greater utility in
predicting airway eosinophilia in asthma than single markers.54
However, no studies of a composite marker of FeNO and serum per-
iostin in predicting severe eosinophilic asthma have been reported.
In a sub-analysis of the Kinki Hokuriku Airway disease Confer-
ence (KiHAC) study, the utility of a composite marker of high FeNO
and high serum periostin levels were examined. FeNO levels at a
constant exhalation ﬂow rate of 50 mL/s were measured using a
Table 1
Characteristics of FeNO and serum periostin.
FeNO Serum periostin
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chemiluminescence analyzer (NOA 280, Sievers, Boulder, CO, USA),
according to the American Thoracic Society (ATS) guidelines.12
Serum periostin levels were measured using enzyme-linked
immunosorbent assay at Shino-Test (Kanagawa, Japan). For FeNO
levels, 25 ppb was used as a cutoff value because the ATS guideline
recommends the consideration of 25 ppb as a cutoff value for
cautious interpretation and monitoring of FeNO levels in patients
on ICS treatment.12 For serum periostin levels, 95 ng/mL was used
as a cutoff value because this value had high speciﬁcity (0.985) to
differentiate between patients with asthma on long-term ICS
treatment and healthy subjects.34 Because periostin expression is
upregulated with the stimulation of IL-4 and IL-1325e27 and high
serum periostin levels strongly reﬂect airway eosinophilic inﬂam-
mation,41 it would be appropriate to consider 95 ng/mL as strictly
reﬂecting the type 2 predominant conditionwhenmeasured by the
current assay system (Shino-Test, Kanagawa, Japan). A total of 121
patients receiving ICS treatment (88 females; mean age, 59 years;
Asthma Control Test® score, 23 points; daily ICS doses, 525 mg
equivalent to ﬂuticasone propionate; patients with history of more
than 10 pack-years were excluded) were stratiﬁed into four groups
according to FeNO levels (cutoff value, 25 ppb) and serum periostin
levels (cutoff value, 95 ng/mL). For the convenience of under-
standing, patients with low FeNO and low serum periostin levels
were categorized as group A (n ¼ 39); high FeNO and low serum
periostin levels as group B (n ¼ 34); low FeNO and high serum
periostin levels as group C (n ¼ 25); and high FeNO and high serum
periostin levels as group D (n ¼ 23) (Fig. 1).
To focus on the role of serum periostin in high FeNO levels
(25 ppb), the clinical aspects of groups B and D were ﬁrst
compared in our previous study.55 Patients in group D (n ¼ 23)
received more intensive treatment, had a history of asthma
admission, and a decline in FEV1 of 30 mL per year more
frequently than those in group B (Table 3). Adherence to medica-
tions was not different between groups B and D (P ¼ 0.56). Despite
receiving intensive treatment, patients in group D had frequent
asthma exacerbations that required systemic corticosteroid treat-
ment over 2 years following enrollment (Fig. 2) and had an odds
ratio of approximately 3 compared with the patients in groups A, B,
and C (n ¼ 97, one patient in group C was lost to follow-up), even
after adjustment for airﬂow limitation (FEV1 < 80% of predicted)
and an episode of asthma exacerbation in the past 6 months. To
examine if this endo-phenotype of severe type-2 inﬂammationwas
genetically associated, we examined the frequency of the GG ge-
notype of IL4RA rs8832. This variant was identiﬁed in a pharma-
cogenetics study of pitrakinra, an inhibitor of IL-4 receptor a that is
a common sub-chain for both IL-4 and IL-13 signaling, as a genetic
marker of good responses to pitrakinra.56 As expected, patients in
group D had a higher frequency of the GG genotype of IL4RA rs8832
(35%) than the remaining patients (15%) in groups A, B, and C
(Fig. 3a). Thus, high levels of both FeNO and serum periostin may
identify patients with severe type-2/eosinophilic inﬂammation,
potentially activated via IL-4 receptor a.
Next, geno-endo-phenotypes of patients with high FeNO levels
only, high serum periostin levels only, or low levels of both are
addressed (Table 3). The GG genotype of POSTN rs3829365 that was
associated with elevated serum periostin levels34 was the least
frequent in group A (low levels of both FeNO and periostin; Fig. 3b),
which was characterized by low blood eosinophil counts. A lack of
elevation in type-2/eosinophilic markers may indicate genetically
different backgrounds in certain patients with asthma. The fre-
quencies of the GG genotype of POSTN rs3829365 were similar in
groups B (high FeNO levels only) and C (high periostin levels only).
The mechanism underlying the lower serum periostin levels in
group B than in group C despite a similar frequency of the GG ge-
notype of POSTN rs3829365 in the two groups remains unknown.
Larger studies on the association between serum periostin levels
and genetic background including POSTN and IL4RA would be
required. Patients in group B had a signiﬁcantly lower frequency of
history of admission due to asthma (Fig. 3c) andwere taller (Fig. 3d)
than those in group C, while group C was characterized by the
Fig. 1. Stratiﬁcation of patients into four groups according to FeNO (<25 ppb, low;
25 ppb, high) and serum periostin levels (<95 ng/mL, low; 95 ng/mL, high).
Table 2
Comparison between FeNO and serum periostin to predict airway eosinophilia and diagnosis of pediatric asthma.
Authors, published year Measurement AUC Cutoff value Sensitivity (%) Speciﬁcity (%) Target
Jia G, 201241 Serum periostin 0.84 25 ng/mL 57 85 Sputum eosinophils 3% or
total biopsy area 22
eosinophils/mm2 in severe
asthma
FeNO 0.79 35 ppb 40 92
Blood eosinophil counts 0.71 e e e
Serum total IgE 0.62 e e e
Wagener AH, 201548 Serum periostin 0.55 26 ng/mL 54 57 Sputum eosinophils 3% in
mild to moderate asthma
FeNO 0.78 42 ppb 63 92
Blood eosinophil counts 0.89 270/mL 78 91
Inoue T, 201650 Serum periostin 0.70 117 ng/mL 75 59 Pediatric asthma
FeNO 0.72 e e e
Blood eosinophil counts 0.84 e e e
e, no description.
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longest disease duration (Fig. 3e) and ICS-untreated period, with a
gap of approximately 10 years among the four groups. Lastly, even
when the cutoff value of FeNO was set at 40 ppb for analysis, this
level was shown to be appropriate to identify patients with poorly
controlled asthma57 and patients with treated asthma with a more
rapid decline in FEV1.23 The following aspects of the four groups
remained signiﬁcantly different: higher frequencies of the Global
Initiative for Asthma (GINA) treatment step 5, subsequent asthma
exacerbations, and more rapid declines in group D than in group B;
taller and lower frequencies of history of admission due to asthma
Fig. 2. Frequency of asthma exacerbations over 2 years following enrollment in patients belonging to the four groups stratiﬁed according to FeNO and serum periostin levels.
Table 3
Patient characteristics in a sub-analysis of KiHAC study.
Group Low FeNO/low periostin High FeNO/low periostin Low FeNO/high periostin High FeNO/high periostin P value* P value**
A (n ¼ 39) B (n ¼ 34) C (n ¼ 25) D (n ¼ 23)
Sex (F/M) 33/6 19/15 19/6 17/6 0.05 0.26
Age at enrollment, years 56 ± 14 59 ± 12 63 ± 13 60 ± 12 0.23 0.90
Age at asthma onset, years 41 ± 16 42 ± 18 35 ± 19 42 ± 16 0.46 0.99
Height, cm 157 ± 9 161 ± 8 156 ± 8 160 ± 7 0.01 0.52
Body mass index, kg/m2 23.6 ± 3.6 23.7 ± 2.7 22.5 ± 3.1 22.1 ± 2.2 0.24 0.02
Smoking history, ex (%) 23 24 20 26 0.97 0.83
Disease duration, years 15 ± 9 17 ± 12 28 ± 18 17 ± 10 0.04 0.77
ICS-untreated period, years 5 ± 6 8 ± 11 18 ± 20 8 ± 9 0.08 0.90
ICS daily maintenance dose, mgy 483 ± 291 525 ± 305 475 ± 314 763 ± 402 0.04 0.04
No. of other controller medications 1.3 ± 1.1 1.0 ± 1.2 0.8 ± 0.8 1.8 ± 1.3 0.02 0.02
Treatment step 5, %z 3 3 0 22 0.004 0.03
Asthma control test (points) 23.2 ± 2.1 23.6 ± 2.5 23.0 ± 3.7 23.1 ± 2.1 0.32 0.12
Serum IgE, IU/mL 112 (0e1300) 298 (0e2090) 212 (10e3740) 233 (27e16,000) 0.15 0.20
Atopy, n (%) 77 76 68 57 0.31 0.11
WBC, cells/mL 5638 ± 1516 6121 ± 1151 5780 ± 1387 5961 ± 1484 0.34 0.41
Eosinophils, cells/mL 164 ± 145 322 ± 170 289 ± 383 385 ± 265 <0.0001 0.71
Neutrophil, cells/mL 3436 ± 1017 3694 ± 969 3364 ± 1107 3613 ± 1469 0.43 0.26
FeNO, ppb 17.1 ± 4.3 52.2 ± 34.3 18.9 ± 4.1 61.9 ± 31.0 <0.0001 0.16
Serum periostin, ng/mL 71.8 ± 17.9 74.1 ± 11.9 118.2 ± 20.9 135.8 ± 44.0 <0.0001 e
History of admission due to asthma, % 13 12 36 39 0.01 0.02
FEV1 at enrollment, % predicted 107 ± 18 99 ± 16 99 ± 29 101 ± 19 0.17 0.57
Annual changes in FEV1, mL/year 2.7 ± 25.9 12.5 ± 37.1 1.9 ± 22.0 19.1 ± 43.1 0.047x 0.003k
Rapid decliner, n (%)¶ 3 (8) 2 (6) 3 (12) 8 (35) 0.007x 0.01k
Mean (±SD) number of asthma
exacerbations per patient
in the 2 subsequent years
0.31 ± 0.83 0.21 ± 0.48 0.83 ± 2.51# 0.57 ± 0.79 0.18 0.05
POSTN rs3829365, GG (%) 23 56 50# 52 0.02 0.78
IL4RA rs8832, GG (%) 15 12 21# 35 0.16 0.04
Results are presented asmeans ± SD, except for IgE [medians (ranges)]. FeNO, exhaled nitric oxide; ICS, inhaled corticosteroids; IgE, immunoglobulin E; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity.
*P values among 4 groups. **P values between groups B and D.
y Equivalent to ﬂuticasone propionate.
z According to the Global Initiative for Asthma 2010 guideline.
x Crude analysis without adjustment with sex, height, age at enrollment, and FEV1 at the ﬁrst measurement.
¶ Rapid decliners were deﬁned as patients with a decline in FEV1  30 mL per year.
k Adjusted by sex, height, age at enrollment, and FEV1 at the ﬁrst measurement.
# Missing in one patient.
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in group B than in group C; the longest disease duration and ICS-
untreated period in group C; the least frequent GG genotype of
POSTN rs3829365 in group A; and the highest frequency of the GG
genotype of IL4RA rs8832 in group D (data not shown).
Conclusively, high levels of both FeNO and serum periostin may
reﬂect severe type-2/eosinophilic airway inﬂammation. However,
each biomarker has speciﬁc characteristics and modiﬁers; patients
with either high FeNO or serum periostin levels only should be
treated with ICS but may not necessarily require as intense treat-
ment as patients with high levels of both markers.
Conclusions
Because patients with severe eosinophilic inﬂammation do not
always complain of symptoms of asthma,58,59 the identiﬁcation of
patients at risk of asthma exacerbations and pulmonary function
decline is clinically important. The use of a composite marker of
FeNO and serum periostin levels may have utility in achieving this
goal.
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